Dectin immunoadhesins and Pneumocystis pneumonia

Infection and Immunity

Volumn 81, Issue 9, 2013, Pages 3451-3462

  Ricks, David M ^a,b   Chen, Kong ^b   Zheng, Mingquan ^b   Steele, Chad ^c   Kolls, Jay K ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c and Clinical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; BETA 1,3 GLUCAN; DECTIN 1; DECTIN IMMUNOADHESIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; UNCLASSIFIED DRUG; ZYMOSAN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CELL WALL; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PNEUMOCYSTIS; PNEUMOCYSTIS MURINA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SURFACE PROPERTY; T LYMPHOCYTE SUBPOPULATION;

EID: 84884264829     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00136-13     Document Type: Article

References (65)

1. Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, Frederick T, Huang L, Beard CB, Kaplan JE. 2004. Current epidemiology of Pneumocystis pneumonia. Emerg. Infect. Dis. 10:1713-1720.
2. Kelley CF, Checkley W, Mannino DM, Franco-Paredes C, Del Rio C, Holguin F. 2009. Trends in hospitalizations for AIDS-associated Pneumocystis jirovecii pneumonia in the United States (1986 to 2005). Chest 136:190-197.
3. Sudjaritruk T, Oberdorfer P, Puthanakit T, Sirisanthana T, Sirisanthana V. 2012. Causes of first hospitalization among 1121 HIV-infected children: comparison of the pre-Pneumocystis jiroveci pneumonia prophylaxis, pre-antiretroviral therapy and antiretroviral therapy periods. Int. J. STD AIDS 23:335-339.
4. Mansharamani NG, Garland R, Delaney D, Koziel H. 2000. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 118:704-711.
5. McKinnell JA, Cannella AP, Kunz DF, Hook EW, Moser SA, Miller LG, Baddley JW, Pappas PG. 2012. Pneumocystis pneumonia in hospitalized patients: a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIVuninfected persons. Transpl. Infect. Dis. 14:510-518.
6. Phair J, Muñoz A, Detels R, Kaslow R, Rinaldo C, Saah A. 1990. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N. Engl. J. Med. 322:161-165.
7. Stansell JD, Osmond DH, Charlebois E, LaVange L, Wallace JM, Alexander BV, Glassroth J, Kvale PA, Rosen MJ, Reichman LB, Turner JR, Hopewell PC. 1997. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am. J. Respir. Crit. Care Med. 155:60-66.
8. Shellito J, Suzara VV, Blumenfeld W, Beck JM, Steger HJ, Ermak TH. 1990. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J. Clin. Invest. 85:1686-1693.
9. Harmsen AG, Stankiewicz M. 1990. Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice. J. Exp. Med. 172:937-945.
10. Roths JB, Marshall JD, Allen RD, Carlson GA, Sidman CL. 1990. Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant scid mice. Natural history and pathobiology. Am. J. Pathol. 136:1173-1186.
11. Hanano R, Reifenberg K, Kaufmann SH. 1996. Naturally acquired Pneumocystis carinii pneumonia in gene disruption mutant mice: roles of distinct T-cell populations in infection. Infect. Immun. 64:3201-3209.
12. French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, Price P, Flexman JP, Tay-Kearney ML. 2000. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 1:107-115.
13. Cheng VC, Yuen KY, Chan WM, Wong SS, Ma ES, Chan RM. 2000. Immunorestitution disease involving the innate and adaptive response. Clin. Infect. Dis. 30:882-892.
14. Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, Gathe JC, Visnegarwala F, Trautner BW. 2002. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 81:213-227.
15. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC, Hamill RJ. 2005. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19:399-406.
16. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, Hogg E, Komarow L. 2009. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 4:e5575. doi:10.1371/journal.pone.0005575.
17. Grant PM, Komarow L, Andersen J, Sereti I, Pahwa S, Lederman MM, Eron J, Sanne I, Powderly W, Hogg E, Suckow C, Zolopa A. 2010. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One 5:e11416. doi:10.1371/journal.pone.0011416.
18. Achenbach CJ, Harrington RD, Dhanireddy S, Crane HM, Casper C, Kitahata MM. 2012. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin. Infect. Dis. 54:424-433.
19. Sun H-Y, Singh N. 2011. Opportunistic infection-associated immune reconstitution syndrome in transplant recipients. Clin. Infect. Dis. 53:168-176.
20. Sun H-Y, Singh N. 2009. Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients. Curr. Opin. Infect. Dis. 22:394-402.
21. Barry SM, Lipman MCI, Deery AR, Johnson MA, Janossy G. 2002. Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med. 3:207-211.
22. Koval CE, Gigliotti F, Nevins D, Demeter LM. 2002. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin. Infect. Dis. 35:491-493.
23. Takahashi T, Nakamura T, Iwamoto A. 2002. Reconstitution of immune responses to Pneumocystis carinii pneumonia in patients with HIV infection who receive highly active antiretroviral therapy. Res. Commun. Mol. Pathol. Pharmacol. 112:59-67.
24. Jagannathan P, Davis E, Jacobson M, Huang L. 2009. Life-threatening immune reconstitution inflammatory syndrome after Pneumocystis pneumonia: a cautionary case series. AIDS 23:1794-1796.
25. Wu AKL, Cheng VCC, Tang BSF, Hung IFN, Lee RA, Hui DS, Yuen KY. 2004. The unmasking of Pneumocystis jiroveci pneumonia during reversal of immunosuppression: case reports and literature review. BMC Infect. Dis. 4:57. doi:10.1186/1471-2334-4-57.
26. Otahbachi M, Nugent K, Buscemi D. 2007. Granulomatous Pneumocystis jiroveci pneumonia in a patient with chronic lymphocytic leukemia: a literature review and hypothesis on pathogenesis. Am. J. Med. Sci. 333:131-135.
27. Wright TW, Gigliotti F, Finkelstein JN, McBride JT, An CL, Harmsen AG. 1999. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J. Clin. Invest. 104:1307-1317.
28. McKinley L, Logar AJ, McAllister F, Zheng M, Steele C, Kolls JK. 2006. Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia. J. Immunol. 177:6215-6226.
29. Bhagwat SP, Wright TW, Gigliotti F. 2010. Anti-CD3 antibody decreases inflammation and improves outcome in a murine model of Pneumocystis pneumonia. J. Immunol. 184:497-502.
30. Drummond RA, Brown GD. 2011. The role of Dectin-1 in the host defence against fungal infections. Curr. Opin. Microbiol. 14:392-399.
31. Singh N. 2008. Novel immune regulatory pathways and their role in immune reconstitution syndrome in organ transplant recipients with invasive mycoses. Eur. J. Clin. Microbiol. Infect. Dis. 27:403-408.
32. Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, Qian K, Vasilakos J, Saijo S, Iwakura Y, Yannelli JR, Yan J. 2011. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans. Blood 117:6825-6836.
33. LeibundGut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, Schweighoffer E, Tybulewicz V, Brown GD, Ruland J, Reis e Sousa C. 2007. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat. Immunol. 8:630-638.
34. Leibundgut-Landmann S, Osorio F, Brown GD, Reis e Sousa C. 2008. Stimulation of dendritic cells via the Dectin-1/Syk pathway allows priming of cytotoxic T-cell responses. Blood 112:4971-4980.
35. Rapaka RR, Goetzman ES, Zheng M, Vockley J, McKinley L, Kolls JK, Steele C. 2007. Enhanced defense against Pneumocystis carinii mediated by a novel Dectin-1 receptor Fc fusion protein. J. Immunol. 178:3702-3712.
36. Steele C, Rapaka RR, Metz A, Pop SM, Williams DL, Gordon S, Kolls JK, Brown GD. 2005. The beta-glucan receptor Dectin-1 recognizes specific morphologies of Aspergillus fumigatus. PLoS Pathog. 1:e42. doi:10.1371/journal.ppat.0010042.
37. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. 2003. Collaborative induction of inflammatory responses by Dectin-1 and Tolllike receptor 2. J. Exp. Med. 197:1107-1117.
38. Zheng M, Shellito JE, Marrero L, Zhong Q, Julian S, Ye P, Wallace V, Schwarzenberger P, Kolls JK. 2001. CD4+ T cell-independent vaccination against Pneumocystis carinii in mice. J. Clin. Invest. 108:1469-1474.
39. Lim SK, Eveland WC, Porter RJ. 1973. Development and evaluation of a direct fluorescent antibody method for the diagnosis of Pneumocystis carinii infections in experimental animals. Appl. Microbiol. 26:666-671.
40. Liu F, Song Y, Liu D. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6:1258-1266.
41. Steele C, Marrero L, Swain S, Harmsen AG, Zheng M, Brown GD, Gordon S, Shellito JE, Kolls JK. 2003. Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor. J. Exp. Med. 198:1677-1688.
42. Di Carlo FJ, Fiore JV. 1958. On the composition of zymosan. Science 127:756-757.
43. Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, Wong SYC, Gordon S. 2002. Dectin-1 is a major beta-glucan receptor on macrophages. J. Exp. Med. 196:407-412.
44. McAllister F, Steele C, Zheng M, Shellito JE, Kolls JK. 2005. In vitro effector activity of Pneumocystis murina-specific T-cytotoxic-1 CD8+ T cells: role of granulocyte-macrophage colony-stimulating factor. Infect. Immun. 73:7450-7457.
45. Leatherbarrow RJ, Dwek RA. 1984. Binding of complement subcomponent C1q to mouse IgG1, IgG2a and IgG2b: a novel C1q binding assay. Mol. Immunol. 21:321-327.
46. Matsumoto Y, Matsuda S, Tegoshi T. 1989. Yeast glucan in the cyst wall of Pneumocystis carinii. J. Protozool. 36:21S-22S.
47. Saijo S, Fujikado N, Furuta T, Chung S, Kotaki H, Seki K, Sudo K, Akira S, Adachi Y, Ohno N, Kinjo T, Nakamura K, Kawakami K, Iwakura Y. 2007. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat. Immunol. 8:39-46.
48. Gantner BN, Simmons RM, Underhill DM. 2005. Dectin-1 mediates macrophage recognition of Candida albicans yeast but not filaments. EMBO J. 24:1277-1286.
49. Netea MG, Gow NAR, Munro CA, Bates S, Collins C, Ferwerda G, Hobson RP, Bertram G, Hughes HB, Jansen T, Jacobs L, Buurman ET, Gijzen K, Williams DL, Torensma R, McKinnon A, MacCallum DM, Odds FC, Van der Meer JWM, Brown AJP, Kullberg BJ. 2006. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J. Clin. Invest. 116:1642-1650.
50. Hohl TM, Van Epps HL, Rivera A, Morgan LA, Chen PL, Feldmesser M, Pamer EG. 2005. Aspergillus fumigatus triggers inflammatory responses by stage-specific beta-glucan display. PLoS Pathog. 1:e30. doi:10.1371/journal.ppat.0010030.
51. Viriyakosol S, Fierer J, Brown GD, Kirkland TN. 2005. Innate immunity to the pathogenic fungus Coccidioides posadasii is dependent on Toll-like receptor 2 and Dectin-1. Infect. Immun. 73:1553-1560.
52. Del Pilar Jiménez-A M, Viriyakosol S, Walls L, Datta SK, Kirkland T, Heinsbroek SEM, Brown G, Fierer J. 2008. Susceptibility to Coccidioides species in C57BL/6 mice is associated with expression of a truncated splice variant of Dectin-1 (Clec7a). Genes Immun. 9:338-348.
53. Wheeler RT, Fink GR. 2006. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog. 2:e35. doi:10.1371/journal.ppat.0020035.
54. Lasbury ME, Durant PJ, Lee C-H. 2003. Pneumocystis carinii cyst is associated with inflammation in the host. J. Eukaryot. Microbiol. 50(Suppl):639-640.
55. Cushion MT, Linke MJ, Ashbaugh A, Sesterhenn T, Collins MS, Lynch K, Brubaker R, Walzer PD. 2010. Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS One 5:e8524. doi:10.1371/journal.pone.0008524.
56. Linke MJ, Ashbaugh A, Collins MS, Lynch K, Cushion MT. 2013. Characterization of a distinct host response profile to Pneumocystis murina asci during clearance of pneumocystis pneumonia. Infect. Immun. 81:984-995.
57. Wang J, Gigliotti F, Maggirwar S, Johnston C, Finkelstein JN, Wright TW. 2005. Pneumocystis carinii activates the NF-kappaB signaling pathway in alveolar epithelial cells. Infect. Immun. 73:2766-2777.
58. Kolls JK, Lei D, Nelson S, Summer WR, Greenberg S, Beutler B. 1995. Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. J. Infect. Dis. 171:570-575.
59. Carmona EM, Lamont JD, Xue A, Wylam M, Limper AH. 2010. Pneumocystis cell wall beta-glucan stimulates calcium-dependent signaling of IL-8 secretion by human airway epithelial cells. Respir. Res. 11:95. doi:10.1186/1465-9921-11-95.
60. Carmona EM, Kottom TJ, Hebrink DM, Moua T, Singh R-D, Pagano RE, Limper AH. 2012. Glycosphingolipids mediate pneumocystis cell wall β-glucan activation of the IL-23/IL-17 axis in human dendritic cells. Am. J. Respir. Cell Mol. Biol. 47:50-59.
61. Gringhuis SI, Den Dunnen J, Litjens M, Van der Vlist M, Wevers B, Bruijns SCM, Geijtenbeek TBH. 2009. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nat. Immunol. 10:203-213.
62. Espinosa V, Rivera A. 2012. Cytokines and the regulation of fungusspecific CD4 T cell differentiation. Cytokine 58:100-106.
63. Antonelli LRV, Mahnke Y, Hodge JN, Porter BO, Barber DL, DerSimonian R, Greenwald JH, Roby G, Mican J, Sher A, Roederer M, Sereti I. 2010. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood 116:3818-3827.
64. Grant PM, Komarow L, Lederman MM, Pahwa S, Zolopa AR, Andersen J, Asmuth DM, Devaraj S, Pollard RB, Richterman A, Kanthikeel S, Sereti I. 2012. Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164. J. Infect. Dis. 206:1715-1723.
65. Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, McDonald JU, Orr SJ, Berger M, Petzold D, Blanchard V, Winkler A, Hess C, Reid DM, Majoul IV, Strait RT, Harris NL, Köhl G, Wex E, Ludwig R, Zillikens D, Nimmerjahn F, Finkelman FD, Brown GD, Ehlers M, Köhl J. 2012. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and Dectin-1. Nat. Med. doi:10.1038/nm.2862.